NeuroSense Therapeutics
NRSN
5 hedge funds and large institutions have $554K invested in NeuroSense Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.
5.52% less ownership
Funds ownership: 11.24% → 5.72% (-5.5%)
17% less funds holding
Funds holding: 6 → 5 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
75% less capital invested
Capital invested by funds: $2.2M → $554K (-$1.64M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$12.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$633K |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$149K |
| 3 |
VPIM
Vanguard Personalized Indexing Management
Oakland,
California
|
-$16.7K |
| 4 |
JP Morgan Chase
New York
|
-$1.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $470K | -$633K | -604,000 | -48% |
|
|
MIH
2
Meitav Investment House
Bene-Beraq,
Israel
| $67.5K | – | – | – |
|
|
3
Citadel Advisors
Miami,
Florida
| $8.78K | +$12.3K | +11,702 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $6.86K | +$10.1K | +9,665 | New |
|
5
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $1K | – | – | – |
|
|
6
Point72 Asset Management
Stamford,
Connecticut
| – | -$149K | -100,000 | Closed |
|
|
VPIM
7
Vanguard Personalized Indexing Management
Oakland,
California
| – | -$16.7K | -11,192 | Closed |
|
|
8
JP Morgan Chase
New York
| – | -$1.9K | -1,304 | Closed |
|
NRSN Hedge Fund Activity: Q3 2023 in Review
5 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q3 2023, worth a combined $554K — down 75% from $2.2M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NRSN and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $12.3K. The largest seller was Armistice Capital, cutting an estimated $633K.
- 5 institutional investors held NeuroSense Therapeutics (NRSN) as of Q3 2023, down from 6 in Q2 2023.
- Funds reported $554K of NeuroSense Therapeutics stock for Q3 2023, down 75% quarter-over-quarter.
- 2 funds opened new NeuroSense Therapeutics positions in Q3 2023 and 3 closed out, a net change of -1 holder.
- The largest NeuroSense Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $12.3K added.
- The largest NeuroSense Therapeutics seller in Q3 2023 was Armistice Capital, an estimated $633K sold.
Based on aggregated 13F filings for Q3 2023.